Summary

Anthelmintic Drugs Market – Scope of Report
TMR’s report on the global anthelmintic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anthelmintic drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anthelmintic drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the anthelmintic drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anthelmintic drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anthelmintic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anthelmintic drugs market.

The report delves into the competitive landscape of the global anthelmintic drugs market. Key players operating in the global anthelmintic drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anthelmintic drugs market profiled in this report.

Key Questions Answered in Global anthelmintic drugs Market Report
• What is the sales/revenue generated by anthelmintic drugs across all regions during the forecast period?
• What are the opportunities in the global anthelmintic drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Anthelmintic Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global anthelmintic drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global anthelmintic drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anthelmintic drugs market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Anthelmintic Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Anthelmintic Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Anthelmintic Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Drug Class, 2017–2031
6.3.1. Benzimidazole
6.3.2. Piperazine
6.3.3. Others
6.4. Market Attractiveness, by Drug Class
7. Global Anthelmintic Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.4. Market Attractiveness, by Route of Administration
8. Global Anthelmintic Drugs Market Analysis and Forecast, By Application
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Application, 2017–2031
8.3.1. Human
8.3.1.1. Parenchymal Neurocysticercosis
8.3.1.2. Gastrointestinal Infections
8.3.2. Animal
8.4. Market Attractiveness, By Application
9. Global Anthelmintic Drugs Market Analysis and Forecast, by Target Pathogen
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Target Pathogen, 2017–2031
9.3.1. Ascaris Lumbricoides (Roundworm)
9.3.2. Trichuris Trichiura (Whipworm)
9.3.3. Enterobius Vermicularis (Pinworm)
9.3.4. Ancylostoma Duodenale (Hookworm)
9.3.5. Others
9.4. Market Attractiveness, by Target Pathogen
10. Global Anthelmintic Drugs Market Analysis and Forecast, by Distribution Channel
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by Distribution Channel, 2017–2031
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.3.4. Veterinary Pharmacies
10.3.5. Veterinary Hospitals & Clinics
10.4. Market Attractiveness, by Distribution Channel
11. Global Anthelmintic Drugs Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Anthelmintic Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Class, 2017–2031
12.2.1. Benzimidazole
12.2.2. Piperazine
12.2.3. Others
12.3. Market Attractiveness, by Drug Class
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Injectable
12.5. Market Attractiveness, by Route of Administration
12.6. Market Value Forecast, By Application, 2017–2031
12.6.1. Human
12.6.1.1. Parenchymal Neurocysticercosis
12.6.1.2. Gastrointestinal Infections
12.6.2. Animal
12.7. Market Attractiveness, By Application
12.8. Market Value Forecast, by Target Pathogen, 2017–2031
12.8.1. Ascaris Lumbricoides (Roundworm)
12.8.2. Trichuris Trichiura (Whipworm)
12.8.3. Enterobius Vermicularis (Pinworm)
12.8.4. Ancylostoma Duodenale (Hookworm)
12.8.5. Others
12.9. Market Attractiveness, by Target Pathogen
12.10. Market Value Forecast, by Distribution Channel, 2017–2031
12.10.1. Hospital Pharmacies
12.10.2. Retail Pharmacies
12.10.3. Online Pharmacies
12.10.4. Veterinary Pharmacies
12.10.5. Veterinary Hospitals & Clinics
12.11. Market Attractiveness, by Distribution Channel
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Drug Class
12.13.2. By Route of Administration
12.13.3. By Application
12.13.4. By Target Pathogen
12.13.5. By Distribution Channel
12.13.6. By Country
13. Europe Anthelmintic Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Class, 2017–2031
13.2.1. Benzimidazole
13.2.2. Piperazine
13.2.3. Others
13.3. Market Attractiveness, by Drug Class
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Injectable
13.5. Market Attractiveness, by Route of Administration
13.6. Market Value Forecast, By Application, 2017–2031
13.6.1. Human
13.6.1.1. Parenchymal Neurocysticercosis
13.6.1.2. Gastrointestinal Infections
13.6.2. Animal
13.7. Market Attractiveness, By Application
13.8. Market Value Forecast, by Target Pathogen, 2017–2031
13.8.1. Ascaris Lumbricoides (Roundworm)
13.8.2. Trichuris Trichiura (Whipworm)
13.8.3. Enterobius Vermicularis (Pinworm)
13.8.4. Ancylostoma Duodenale (Hookworm)
13.8.5. Others
13.9. Market Attractiveness, by Target Pathogen
13.10. Market Value Forecast, by Distribution Channel, 2017–2031
13.10.1. Hospital Pharmacies
13.10.2. Retail Pharmacies
13.10.3. Online Pharmacies
13.10.4. Veterinary Pharmacies
13.10.5. Veterinary Hospitals & Clinics
13.11. Market Attractiveness, by Distribution Channel
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Drug Class
13.13.2. By Route of Administration
13.13.3. By Application
13.13.4. By Target Pathogen
13.13.5. By Distribution Channel
13.13.6. By Country/Sub-region
14. Asia Pacific Anthelmintic Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Drug Class, 2017–2031
14.2.1. Benzimidazole
14.2.2. Piperazine
14.2.3. Others
14.3. Market Attractiveness, by Drug Class
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Injectable
14.5. Market Attractiveness, by Route of Administration
14.6. Market Value Forecast, By Application, 2017–2031
14.6.1. Human
14.6.1.1. Parenchymal Neurocysticercosis
14.6.1.2. Gastrointestinal Infections
14.6.2. Animal
14.7. Market Attractiveness, By Application
14.8. Market Value Forecast, by Target Pathogen, 2017–2031
14.8.1. Ascaris Lumbricoides (Roundworm)
14.8.2. Trichuris Trichiura (Whipworm)
14.8.3. Enterobius Vermicularis (Pinworm)
14.8.4. Ancylostoma Duodenale (Hookworm)
14.8.5. Others
14.9. Market Attractiveness, by Target Pathogen
14.10. Market Value Forecast, by Distribution Channel, 2017–2031
14.10.1. Hospital Pharmacies
14.10.2. Retail Pharmacies
14.10.3. Online Pharmacies
14.10.4. Veterinary Pharmacies
14.10.5. Veterinary Hospitals & Clinics
14.11. Market Attractiveness, by Distribution Channel
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Drug Class
14.13.2. By Route of Administration
14.13.3. By Application
14.13.4. By Target Pathogen
14.13.5. By Distribution Channel
14.13.6. By Country/Sub-region
15. Latin America Anthelmintic Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Drug Class, 2017–2031
15.2.1. Benzimidazole
15.2.2. Piperazine
15.2.3. Others
15.3. Market Attractiveness, by Drug Class
15.4. Market Value Forecast, by Route of Administration, 2017–2031
15.4.1. Oral
15.4.2. Injectable
15.5. Market Attractiveness, by Route of Administration
15.6. Market Value Forecast, By Application, 2017–2031
15.6.1. Human
15.6.1.1. Parenchymal Neurocysticercosis
15.6.1.2. Gastrointestinal Infections
15.6.2. Animal
15.7. Market Attractiveness, By Application
15.8. Market Value Forecast, by Target Pathogen, 2017–2031
15.8.1. Ascaris Lumbricoides (Roundworm)
15.8.2. Trichuris Trichiura (Whipworm)
15.8.3. Enterobius Vermicularis (Pinworm)
15.8.4. Ancylostoma Duodenale (Hookworm)
15.8.5. Others
15.9. Market Attractiveness, by Target Pathogen
15.10. Market Value Forecast, by Distribution Channel, 2017–2031
15.10.1. Hospital Pharmacies
15.10.2. Retail Pharmacies
15.10.3. Online Pharmacies
15.10.4. Veterinary Pharmacies
15.10.5. Veterinary Hospitals & Clinics
15.11. Market Attractiveness, by Distribution Channel
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Drug Class
15.13.2. By Route of Administration
15.13.3. By Application
15.13.4. By Target Pathogen
15.13.5. By Distribution Channel
15.13.6. By Country/Sub-region
16. Middle East & Africa Anthelmintic Drugs Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Drug Class, 2017–2031
16.2.1. Benzimidazole
16.2.2. Piperazine
16.2.3. Others
16.3. Market Attractiveness, by Drug Class
16.4. Market Value Forecast, by Route of Administration, 2017–2031
16.4.1. Oral
16.4.2. Injectable
16.5. Market Attractiveness, by Route of Administration
16.6. Market Value Forecast, By Application, 2017–2031
16.6.1. Human
16.6.1.1. Parenchymal Neurocysticercosis
16.6.1.2. Gastrointestinal Infections
16.6.2. Animal
16.7. Market Attractiveness, By Application
16.8. Market Value Forecast, by Target Pathogen, 2017–2031
16.8.1. Ascaris Lumbricoides (Roundworm)
16.8.2. Trichuris Trichiura (Whipworm)
16.8.3. Enterobius Vermicularis (Pinworm)
16.8.4. Ancylostoma Duodenale (Hookworm)
16.8.5. Others
16.9. Market Attractiveness, by Target Pathogen
16.10. Market Value Forecast, by Distribution Channel, 2017–2031
16.10.1. Hospital Pharmacies
16.10.2. Retail Pharmacies
16.10.3. Online Pharmacies
16.10.4. Veterinary Pharmacies
16.10.5. Veterinary Hospitals & Clinics
16.11. Market Attractiveness, by Distribution Channel
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Drug Class
16.13.2. By Route of Administration
16.13.3. By Application
16.13.4. By Target Pathogen
16.13.5. By Distribution Channel
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. Novartis AG
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Zoetis, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Amneal Pharmaceuticals, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Cipla Inc.
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. Sun Pharmaceutical Industries Ltd.
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. GlaxoSmithKline plc
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Bayer AG
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Merck & Co. Inc. (Intervet Inc.)
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Boehringer Ingelheim International GmbH
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview